OpenAI acquires biotech startup Orchestra Bio
OpenAI has acquired Orchestra Bio to integrate its team and technology into the development of Rosalind, an AI model designed for life sciences research.
OpenAI has completed the acquisition of Orchestra Bio, a startup focused on biotechnology applications. The move brings Orchestra Bio’s personnel and proprietary technology into OpenAI’s research division.
The integration will center on the development of Rosalind, an AI model dedicated to life sciences research, and its associated interface, the Rosalind Workbench. This tool aims to assist researchers by streamlining the experimental design process and facilitating the analysis of complex biological datasets.
By absorbing the startup's resources, OpenAI is moving to deepen its vertical integration within the scientific research sector. The acquisition signals a shift toward deploying specialized AI capabilities for laboratory workflows, moving beyond general-purpose large language models.